Data from Advances in Precision Cancer Care - Curated by EPG Health - Last updated 19 October 2018

About Advances in Precision Cancer Care

Advances in Precision Cancer Care aims to bring you the latest news and some of the most exciting developments in precision cancer care.

Our first reports come from ESMO Congress 2018.

 

Blog posts by Advances in Precision Cancer Care

ESMO 2018 | Day 2 highlights

Saturday’s ESMO 2018 report comes from Presidential Symposium 1, moderated by Andrés Cervantes (Valencia, ES) and Josep Tabernero (Barcelona, ES), discussing the scientific results and clinical implications of new data from the phase 3 IMpassion130, PALOMA-3 and SOLAR-1 trials. 

Posted 1 month ago

Advances in Precision Cancer Care

Take a look at some of the most exciting developments in precision cancer care coming from ESMO 2018.

Posted 1 month ago

ESMO 2018 | Day 4 highlights

In our final report from ESMO 2018 we share insights from the Proffered paper session - Gastrointestinal tumours, colorectal, moderated by Dirk Arnold (Hamburg, DE) and Alfredo Falcone (Pisa, IT). Here, we cover survival data from the MODUL trial, comparing maintenance fluorouracil-bevacizumab and fluorouracil-bevacizumab plus atezolizumab in BRAF wild-type disease, and [in TRIBE2] consider the impact on PFS2 of an intensified treatment strategy versus a standard, sequential treatment strategy.

Posted 1 month ago

ESMO 2018 | Day 3 highlights

Sunday’s ESMO 2018 report comes from Presidential Symposium 2, moderated by Fortunato Ciardiello (Napoli, IT) and Josep Tabernero (Barcelona, ES). Here, we share key data and discussions from presentations on the STAMPEDE trial, looking at the role of prostate radiotherapy for patients with newly diagnosed metastatic prostate cancer and JAVELIN Renal 101, assessing avelumab plus axitinib as a first-line treatment option for patients with advanced renal cell carcinoma. 

Posted 1 month ago

ESMO 2018 | Day 1 highlights

Today’s report come from the Proffered paper session - NSCLC, metastatic, focusing on presentations LBA50 and LBA51 discussing mechanisms of acquired resistance to osimertinib from the phase III trials FLAURA and AURA3, respectively.

Posted 1 month ago